0.3901
前日終値:
$0.397
開ける:
$0.4
24時間の取引高:
97,822
Relative Volume:
0.85
時価総額:
$10.93M
収益:
-
当期純損益:
$-58.52M
株価収益率:
-0.1867
EPS:
-2.09
ネットキャッシュフロー:
$-45.03M
1週間 パフォーマンス:
-21.82%
1か月 パフォーマンス:
-47.21%
6か月 パフォーマンス:
-71.10%
1年 パフォーマンス:
-81.94%
Nextcure Inc Stock (NXTC) Company Profile
名前
Nextcure Inc
セクター
電話
240-399-4900
住所
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
NXTC を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
NXTC
Nextcure Inc
|
0.3901 | 10.93M | 0 | -58.52M | -45.03M | -2.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2022-11-04 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
2022-03-01 | 開始されました | Ladenburg Thalmann | Buy |
2021-03-05 | アップグレード | Truist | Hold → Buy |
2021-01-15 | ダウングレード | BofA Securities | Neutral → Underperform |
2020-07-16 | アップグレード | The Benchmark Company | Hold → Buy |
2020-07-13 | ダウングレード | ROTH Capital | Buy → Neutral |
2020-07-13 | ダウングレード | SunTrust | Buy → Hold |
2020-06-01 | ダウングレード | BofA/Merrill | Buy → Neutral |
2020-06-01 | ダウングレード | The Benchmark Company | Buy → Hold |
2020-05-26 | 開始されました | JMP Securities | Mkt Outperform |
2020-03-24 | 開始されました | The Benchmark Company | Buy |
2020-03-02 | 開始されました | ROTH Capital | Buy |
2020-01-13 | 開始されました | SunTrust | Buy |
2019-12-05 | 開始されました | Needham | Buy |
2019-11-26 | 開始されました | BTIG Research | Buy |
2019-07-09 | 開始されました | BofA/Merrill | Buy |
2019-06-03 | 開始されました | Morgan Stanley | Overweight |
2019-06-03 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Nextcure Inc (NXTC) 最新ニュース
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Cancer Therapy Breakthrough? NextCure's Major Presentation at Needham Healthcare Conference - Stock Titan
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire Inc.
CLASS ACTION UPDATE for PLAN, NXTC and BTU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
NextCure stock plunges to 52-week low, hits $0.46 - Investing.com India
NextCure stock plunges to 52-week low, hits $0.46 By Investing.com - Investing.com Australia
NextCure stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.55 amid market challenges - Investing.com India
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
H.C. Wainwright maintains Buy rating, $3 target on NextCure stock - Investing.com India
H.C. Wainwright maintains Buy rating, $3 target on NextCure stock By Investing.com - Investing.com South Africa
NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
NextCure stock plunges to 52-week low at $0.66 amid market challenges - Investing.com Australia
NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World
2 Net Current Asset Value Stocks to Consider - GuruFocus.com
Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles - MSN
NextCure Reports 2024 Financials and Strategic Progress - TipRanks
NextCure Provides Business Update and Reports Full Year 2024 Financial Results - The Manila Times
NextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill Cohorts - Nasdaq
Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? - StockTitan
Korea Biotech Roundup: Orum, DongKook Price IPOs Below Band - insights.citeline.com
NextCure stock plunges to 52-week low, hits $0.69 - MSN
NextCure stock plunges to 52-week low, hits $0.69 By Investing.com - Investing.com Canada
Ventia Strengthens Leadership with New Company Secretary Appointment - MSN
Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? - Yahoo Finance
Eaton Vance Tax-Managed Diversified Equity Income Fund declares $0.0992 dividend - MSN
NextCure Faces Potential Delisting from Nasdaq Global Select Market Due to Minimum Bid Requirement Non-Compliance - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Geode Capital Management LLC Acquires 27,812 Shares of NextCure, Inc. (NASDAQ:NXTC) - Defense World
Jane Street Group LLC Has $125,000 Holdings in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World
NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_ - Defense World
LigaChem Biosciences doses first patient in phase 1 trial of LNCB74 cancer drugCHOSUNBIZ - 조선비즈
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 as Therapeutic for Treating Multiple Cancers - Marketscreener.com
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - The Manila Times
NextCure Advances Cancer Treatment: First Patient Dosed in LNCB74 Phase 1 Trial - StockTitan
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
NextCure stock hits 52-week low at $0.87 amid market challenges - Investing.com Australia
NextCure stock hits 52-week low at $0.87 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.99 amid market challenges - Investing.com India
The Buckle, Inc. Announces Dividend PayoutsKearney, NE — The Buckle, Inc. (NYSE: BKE) disclosed plans for upcoming shareholder dividend payments following the quarterly meeting of its Board of Directors on December 9, 2024. The company greenlighte - Defense World
FDA clears IND for B7-H4-targeting ADC - BioWorld Online
NextCure Announces Acceptance of IND Application for LNCB74 - The Manila Times
NextCure, Inc. Announces Acceptance of IND Application for LNCB74 - Marketscreener.com
NextCure's Cancer Drug LNCB74 Secures FDA IND Approval for Phase 1 Clinical Trials - StockTitan
Nextcure Inc (NXTC) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):